Adlante 4 Capsule is a medication designed to combat cancer, utilized in the treatment of various cancer types. Cancer arises from the uncontrolled proliferation of abnormal cells. This medication serves as a first-line treatment for hepatocellular carcinoma, addresses differentiated thyroid cancer in patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory conditions, and is also used in conjunction with pembrolizumab for advanced renal cell carcinoma and advanced endometrial cancer.
Adlante 4 Capsule contains Lenvatinib, classified as a kinase inhibitor. Its mechanism involves blocking the action of the enzyme tyrosine kinase, thereby halting the abnormal proliferation of cancer cells.
Potential side effects of Adlante 4 Capsule include diarrhoea, reduced appetite, nausea, vomiting, fatigue, itching, rash, headaches, cough, abdominal discomfort, hoarseness, and dizziness. If any of these side effects are troublesome, please notify your doctor. It is essential to take Adlante 4 Capsule exactly as prescribed by your healthcare provider and not exceed the recommended dosage.
Should you have an allergy to Adlante 4 Capsule or any of its ingredients, inform your physician. Prior to starting Adlante 4 Capsule, disclose any history of liver or kidney disease, calcium deficiency, heart issues, hypertension, seizures, bleeding disorders, vision impairments, or previous blood clots to your doctor. This medication is known to pose risks of embryo-fetal toxicity and is not advised for use during pregnancy or while breastfeeding.
